Cypress Asset Management’s AbbVie ABBV Stock Holding History

Cypress Asset Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	$951K	Sell	4,160 -5	-0.1%	-$1.14K	0.21%	73
2025 Q3	$964K	Sell	4,165 -12	-0.3%	-$2.44K	0.22%	71
2025 Q2	$775K	Buy	4,177 +515	+14%	+$95.7K	0.19%	75
2025 Q1	$767K	Sell	3,662 -86	-2%	-$16.7K	0.21%	73
2024 Q4	$666K	Sell	3,748 -110	-3%	-$20.2K	0.17%	77
2024 Q3	$762K	Buy	3,858 +80	+2%	+$14.9K	0.19%	75
2024 Q2	$648K	Sell	3,778 -372	-9%	-$61.6K	0.17%	76
2024 Q1	$756K	Sell	4,150 -2,825	-41%	-$487K	0.2%	80
2023 Q4	$1.08M	Sell	6,975 -730	-9%	-$106K	0.33%	69
2023 Q3	$1.15M	Sell	7,705 -3,757	-33%	-$552K	0.38%	64
2023 Q2	$1.55M	Sell	11,462 -1,948	-15%	-$286K	0.5%	53
2023 Q1	$2.14M	Sell	13,410 -17	-0.1%	-$2.6K	0.74%	44
2022 Q4	$2.17M	Sell	13,427 -540	-4%	-$82.8K	0.79%	43
2022 Q3	$1.88M	Sell	13,967 -60	-0.4%	-$8.61K	0.72%	44
2022 Q2	$2.15M	Buy	14,027 +25	+0.2%	+$3.82K	0.77%	42
2022 Q1	$2.27M	Sell	14,002 -739	-5%	-$107K	0.67%	47
2021 Q4	$2M	Buy	14,741 +34	+0.2%	+$4.02K	0.48%	65
2021 Q3	$1.59M	Buy	14,707 +10	+0.1%	+$1.14K	0.41%	70
2021 Q2	$1.66M	Sell	14,697 -215	-1%	-$24.2K	0.42%	70
2021 Q1	$1.61M	Sell	14,912 -135	-0.9%	-$14.4K	0.45%	68
2020 Q4	$1.61M	Buy	15,047 +394	+3%	+$37.9K	0.45%	71
2020 Q3	$1.28M	Buy	14,653 +345	+2%	+$32.5K	0.4%	77
2020 Q2	$1.41M	Buy	14,308 +4,553	+47%	+$401K	0.47%	65
2020 Q1	$743K	Buy	9,755 +5,725	+142%	+$488K	0.32%	85
2019 Q4	$357K	Sell	4,030 -450	-10%	-$37.4K	0.12%	112
2019 Q3	$339K	Sell	4,480 -100	-2%	-$6.86K	0.12%	121
2019 Q2	$333K	Sell	4,580 -1,765	-28%	-$139K	0.11%	121
2019 Q1	$511K	Sell	6,345 -625	-9%	-$51.1K	0.17%	108
2018 Q4	$643K	Sell	6,970 -1,015	-13%	-$89.3K	0.24%	98
2018 Q3	$755K	Sell	7,985 -3,125	-28%	-$296K	0.22%	105
2018 Q2	$1.03M	Sell	11,110 -1,500	-12%	-$146K	0.3%	87
2018 Q1	$1.19M	Sell	12,610 -7,443	-37%	-$818K	0.35%	85
2017 Q4	$1.94M	Sell	20,053 -530	-3%	-$50K	0.42%	68
2017 Q3	$1.83M	Sell	20,583 -410	-2%	-$31.2K	0.39%	76
2017 Q2	$1.52M	Sell	20,993 -3,650	-15%	-$245K	0.31%	82
2017 Q1	$1.61M	Sell	24,643 -1,065	-4%	-$67K	0.31%	86
2016 Q4	$1.61M	Sell	25,708 -130	-0.5%	-$7.93K	0.31%	83
2016 Q3	$1.63M	Sell	25,838 -525	-2%	-$34K	0.32%	84
2016 Q2	$1.63M	Sell	26,363 -2,665	-9%	-$162K	0.32%	86
2016 Q1	$1.66M	Buy	29,028 +105	+0.4%	+$5.85K	0.34%	85
2015 Q4	$1.71M	Hold	28,923	–	–	0.34%	80
2015 Q3	$1.57M	Sell	28,923 -15	-0.1%	-$976	0.33%	81
2015 Q2	$1.94M	Buy	28,938 +299	+1%	+$19.5K	0.37%	78
2015 Q1	$1.68M	Sell	28,639 -1,075	-4%	-$64.9K	0.31%	86
2014 Q4	$1.94M	Buy	29,714 +1,900	+7%	+$120K	0.36%	72
2014 Q3	$1.61M	Buy	27,814 +750	+3%	+$41.6K	0.29%	87
2014 Q2	$1.53M	Buy	27,064 +550	+2%	+$28.9K	0.26%	94
2014 Q1	$1.36M	Buy	26,514 +3,000	+13%	+$152K	0.25%	95
2013 Q4	$1.24M	Buy	23,514 +1,820	+8%	+$89.5K	0.22%	98
2013 Q3	$970K	Sell	21,694 -200	-0.9%	-$8.87K	0.18%	104
2013 Q2	$905K	Buy	+21,894	New	+$958K	0.17%	103

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Cypress Asset Management's ABBV Position: Q4 2025 in Review

Cypress Asset Management reduced its AbbVie (ABBV) stake by 0.12% in Q4 2025, selling an estimated $1.14K and leaving 4,160 shares worth $951K. The position accounts for 0.21% of the portfolio, ranked #73.

Cypress Asset Management first reported a position in ABBV in Q2 2013 and has held it in 51 quarters since. The position peaked at $2.27M in Q1 2022. 4,145 funds tracked by Wall St. Rank hold ABBV as of Q4 2025.

Cypress Asset Management held 4,160 shares of AbbVie worth $951K as of Q4 2025.
Cypress Asset Management sold 5 AbbVie shares in Q4 2025, an estimated $1.14K.
AbbVie made up 0.21% of Cypress Asset Management's portfolio in Q4 2025, its #73 holding.
Cypress Asset Management first reported a position in AbbVie in Q2 2013 and has held it in 51 quarters since.
Cypress Asset Management's AbbVie position peaked at $2.27M in Q1 2022.
4,145 funds tracked by Wall St. Rank held AbbVie as of Q4 2025.

Based on Cypress Asset Management's 13F filing for Q4 2025, filed 29 Jan 2026.